MCK Related Analyst Ratings
-
AmerisourceBergen (ABC) Likely to Score Another Win Against McKesson (MCK)
-
Northcoast Research Downgrades McKesson (MCK) to Neutral
-
Is the PSS/McKesson Deal a Curse or a Blessing in Disguise for athenahealth (ATHN)?
-
Analysts say McKesson (MCK) Earnings Bias Points North of Estimates
-
Mizuho Securities Upgrades McKesson (MCK) to Buy
-
Morgan Stanley Downgrades McKesson (MCK) to Equalweight
-
JMP Resumes PBM Providers: CVS, MCK, ESRX at Outperform, CTRX at Market Perform
-
ISI Group Starts McKesson (MCK) at Overweight
-
Goldman Sachs Adds AmerisourceBergen (ABC) to Conviction Buy, Removes McKesson (MCK)
-
UBS Maintains a 'Buy' on Cardinal Health (CAH); Color on Safeway Contract
-
Auriga Downgrades McKesson (MCK) to Hold; Drilling Down...Strong Q4 From Stock Buybacks
-
Raymond James Downgrades McKesson (MCK) to Market Perform
-
Goldman Sachs Boosts Numbers on McKesson (MCK) To Include Katz, Keeps Top Rating
-
Auriga Reiterates a 'Buy' on McKesson (MCK); Center Stage of Strong Qtr Include Katz Acquisition and Increased Buyback
-
CORRECTION: Jefferies Raises Price Target On McCormick (MKC)
-
Barclays on U.S. Health Care Distribution & Technology: VA Contract Announcement Could Be Early January; No Change in Our Expectations
-
Barclays Maintains an 'Overweight' on McKesson (MCK); Focus on Paragon Expanded Following Halt of Horizon ERM Development
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Goldman Sachs Deletes AmerisourceBergen (ABC) from Conviction Buy List
-
Goldman Sachs Adds McKesson (MCK) to Conviction Buy List
-
UBS Maintains a 'Buy' on McKesson (MCK); Blowout F2Q12
-
Citi Upgrades McKesson (MCK) to Buy
-
Auriga Reiterates a 'Buy' on McKesson (MCK); Another Strong Q: Should Only Get Better
-
Edward Jones Starts McKesson (MCK) at Hold
-
Barclays Maintains an 'Overweight' on McKesson (MCK); Set to Succeed Again in FY12: Estimates, Target Up-Ticked Again After Visit
-
FBR Capital Maintains an 'Outperform' on Cerner (CERN); Adds to Top Pick List
-
Cowen Starts Healthcare Stocks: ESRX, MHS, MDRX, CAH, MCK, ABC at Outperform, CERN, SXCI, QSII at Neutral
-
UBS Maintains a 'Buy' on McKesson (MCK); Q4 Earnings Preview
-
Barclays Maintains an 'Overweight' on McKesson (MCK); 10-year Anniversary, Bright Future for Branded Generic
-
Goldman Raises Estimates & Price Target on McKesson (MCK), Maintains Buy Rating
-
Auriga Reiterates a 'Buy' on McKesson (MCK); Raises PT & Estimates
-
UBS Maintains a 'Buy' on McKesson (MCK); Another Robust Quarter
-
Raymond James Upgrades McKesson (MCK) to Outperform Following Q3 Report
-
Susquehanna Raises Estimates & Price Target on McKesson (MCK), Maintains Positive Rating
-
Goldman Sachs Boosts Price Target On McKesson (MCK) to $87
-
Deutsche Bank Reiterates a 'Buy' on McKesson (MCK); Strong Q + Incr. Guidance = Core Healthcare Holding
-
UBS on U.S. Healthcare Distribution: 2011 Outlook and Quarterly Preview
-
Citi Downgrades McKesson (MCK) to Hold
-
UBS Maintains a 'Buy' on McKesson (MCK); A Closer Look at US Oncology
-
Auriga Raises Price Target on McKesson (MCK), Maintains Buy Rating
-
Goldman Sachs Rates McKesson (MCK) at Buy
-
Standpoint Research Downgrades McKesson (MCK) to Hold
-
Barclays maintains an 'Overweight' on McKesson (MCK); Initial Thoughts on Court Order Delaying US Oncology Acquisition
-
Susquehanna Raises Price Target on McKesson (MCK), Maintains Positive Rating
-
Bernstein Upgrades McKesson (MCK) to Outperform
-
UBS Adds Baxter (BAX) to 'Key Calls' List, Removes KO, TEL, MCK
-
UBS Adjusts Estimates & PT on McKesson (MCK); F2Q11 Preview: Distribution To Offset HCIT
-
Health Care Distribution & Technology: Barclays Capital Weekly Perspectives
-
Susquehanna Initiates Coverage on McKesson Corp (MCK) with a Positive
-
UPDATE - UBS Downgrades Omnicare (OCR) to Neutral; Moving To The Sidelines Post +25% Rally
Back to MCK Stock Lookup
